Siemens Medical Solutions

Oct 23, 2007

2007 10 22 14 17 11 706

(Booth 7713) Siemens Medical Solutions of Malvern, PA, is expected to highlight its new Symbia E SPECT camera at the RSNA conference.

Introduced in October 2007, Symbia E represents a redesign of the company's e.cam gamma camera with an enhanced chassis and electronics. The SPECT imager peforms oncology, cardiology, neurology, and general imaging applications, and can be equipped with special positioning pallets for mammography. It also offers a tilting detector for optimized planar imaging.

The system features Siemens' syngo software for image acquisition, processing, and review through an integrated physician worklist and shortened imaging times for cardiology and oncology patients through cardioFlash and oncoFlash reconstruction software packages.

In addition, Symbia E offers the company's c.clear attenuation correction, which was developed on the Siemens c.cam dedicated cardiac SPECT camera.

Patient examples of SPECT/CT and PET/CT RECIP 1.0. (A) SPECT and PET maximum-intensity projection (MIP) images in 74-year-old man with mCRPC. Serum PSA level at baseline was 449 ng/mL and slightly increased to 525 ng/mL after two cycles of Lu-177 PSMA. Eastern Cooperative Oncology Group (ECOG) score was 2 at baseline and increased to 3 after 2 cycles. The patient was classified by readers as RECIP-progressive disease on both SPECT and PET. Overall survival was 4.7 months. Two cycles of Lu-177 PSMA were administered. (B) SPECT and PET MIP images in 74-year-old man with mCRPC. Serum PSA level was 231 ng/mL at baseline and decreased to 12.5 ng/mL after 2 cycles of Lu-177 PSMA. ECOG score was less than 2 at baseline and after 2 cycles of Lu-177 PSMA. The patient was classified by readers as RECIP-partial response on both SPECT and PET. Overall survival was 14.3 months. Four cycles of Lu-177 PSMA were administered.

SPECT/CT predicts overall survival in Pluvicto patients

April 25, 2025

Imaging Life Issue 20 now available

Imaging Life Issue 20 now available

April 1, 2025

Manufacturing Facility Process

Eckert & Ziegler signs manufacturing deal with Pentixapharm

April 24, 2025

UM launches new research reactor with $10M deal

April 23, 2025

SPECT/CT predicts overall survival in Pluvicto patients

New evidence supports using SPECT/CT scans along with serum PSA levels to evaluate early patient responses to Pluvicto treatment.

April 25, 2025

Patient examples of SPECT/CT and PET/CT RECIP 1.0. (A) SPECT and PET maximum-intensity projection (MIP) images in 74-year-old man with mCRPC. Serum PSA level at baseline was 449 ng/mL and slightly increased to 525 ng/mL after two cycles of Lu-177 PSMA. Eastern Cooperative Oncology Group (ECOG) score was 2 at baseline and increased to 3 after 2 cycles. The patient was classified by readers as RECIP-progressive disease on both SPECT and PET. Overall survival was 4.7 months. Two cycles of Lu-177 PSMA were administered. (B) SPECT and PET MIP images in 74-year-old man with mCRPC. Serum PSA level was 231 ng/mL at baseline and decreased to 12.5 ng/mL after 2 cycles of Lu-177 PSMA. ECOG score was less than 2 at baseline and after 2 cycles of Lu-177 PSMA. The patient was classified by readers as RECIP-partial response on both SPECT and PET. Overall survival was 14.3 months. Four cycles of Lu-177 PSMA were administered.

PET scans identify people at early risk for cognitive decline

Amyloid PET scans in people with early signs of Alzheimer’s can identify those at higher risk of progressing to cognitive decline.

April 24, 2025

Ad Voxels Thumbnail

Eckert & Ziegler signs manufacturing deal with Pentixapharm

By AuntMinnie.com staff writers

Eckert & Ziegler Radiopharma GmbH has signed a manufacturing agreement with Pentixapharm.

April 24, 2025

Manufacturing Facility Process

UM launches new research reactor with $10M deal

By AuntMinnie.com staff writers

The University of Missouri (UM) has inked a $10 million deal with a Korean consortium.

April 23, 2025

Shine Technologies, Modawina Medical sign UAE distribution deal

By AuntMinnie.com staff writers

Shine Technologies has signed an agreement with Modawina Medical Company to distribute Shine’s lutetium-177 isotope in the UAE.

April 22, 2025

Atom Nuclear Lab 400

Combined PET scans predict the progression of Alzheimer’s disease

Combining information from amyloid PET and FDG-PET scans can predict progression from mild cognitive impairment to Alzheimer's.

April 21, 2025

Ad Pet Fdg Thumbnail

PET scans predict outcomes for patients undergoing CAR T-cell therapy

PET scans performed at one or three months after patients with large B-cell lymphoma begin CAR T-cell therapy can indicate whether they are responding to the treatment.

April 18, 2025

Pet Scan Patient

New theranostics PET tracer shows promise

A new gallium-68 (Ga-68) PET/CT radiotracer appears superior over F-18 FDG for detecting bone metastases.

April 17, 2025

Images of a 69-year-old man diagnosed with prostate cancer who had a history of endocrine therapy for two years. (a) The maximum intensity projection (MIP) image of F-18 FDG showed moderate radiotracer uptake in a thoracic vertebra. (e) The MIP image of Ga-68 DOTA-IBA demonstrated more lesions in the cervical vertebra and pelvis. (b) An osteoblastic lesion in the C3 vertebra right attachment (curved arrows) was negative on F-18 FDG (SUVmax = 2.0) and positive on Ga-68 DOTA-IBA (SUVmax = 8.7). (c) Another osteoblastic lesion in the T10 vertebra left side (arrowheads) was both positive on F-18 FDG (SUVmax = 5.2) and positive on Ga-68 DOTA-IBA (SUVmax = 35.0). (d) Osteoblastic lesions in bilateral ilium (dotted arrows and arrows) were negative on F-18 FDG (left: SUVmax = 1.4, right: SUVmax = 1.6) and positive on Ga-68 DOTA-IBA (left: SUVmax = 7.6, right: SUVmax = 8.7). Follow-up imaging three months later confirmed the presence of these bone metastases. Image and caption available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of Scientific Reports.

PET/CT detects vasculitis following COVID-19 vaccination

A whole-body F-18 FDG-PET/CT scan was key in identifying medium-vessel vasculitis in a patient following a Moderna COVID-19 vaccination.

April 11, 2025

Covid 19 Vax Thumbnail

PET links depressive symptoms to Alzheimer’s brain pathology

Researchers have reported that worsening depression in older adults is related to higher levels of Alzheimer’s pathology.

April 10, 2025

IMV: PET procedure volumes continue strong growth trend

By Davin Korstjens

Overall PET procedure volumes increased by 12.2% in 2024, according to the IMV 2025 PET Market Summary Report.

April 10, 2025

Having a father with Alzheimer's could mean higher risk of the disease

By Kate Madden Yee

Having a father with Alzheimer's may be tied to a greater spread of the tau protein in the brain, researchers have reported.

April 9, 2025

Page 1 of 603